Bo Qiu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Bo Qiu has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
Christina Phuong
1 shared publication- Katherine K. Matthay
Department of Pediatrics University of California San Francisco California USA
1 shared publication Sabine Mueller
1 shared publication- Steve E. Braunstein
Department of Radiation Oncology, University of California at San Francisco, UCSF Benioff Children's Hospital, San Francisco, CA
1 shared publication
Latest Publications
- Open Access
- 6 April 2023
- Published by Elsevier in Journal of the National Cancer Center
- Vol. 3 (2) , 141-149
Precision based approach to tailoring radiotherapy in the multidisciplinary management of pediatric central nervous system tumors
- 6 April 2023
- Published by Elsevier in Journal of the National Cancer Center
- Vol. 3 (2) , 141-149
Open AccessPrecision based approach to tailoring radiotherapy in the multidisciplinary management of pediatric central nervous system tumors
- Top Cited Papers
- 25 May 2022
- Published by Springer Nature in Nature Reviews Clinical Oncology
- Vol. 19 (8) , 515-533
Advancing therapy for neuroblastoma
Neuroblastomas are tumours of sympathetic origin, with a heterogeneous clinical course ranging from localized or spontaneously regressing to widely metastatic disease. Neuroblastomas recapitulate many of the features of sympathoadrenal development, which have been directly targeted to improve the survival outcomes in patients with high-risk disease. Over the past few decades, improvements in the 5-year survival of patients with metastatic neuroblastomas, from 50%, have resulted from clinical trials incorporating high-dose chemotherapy with autologous stem cell transplantation, differentiating agents and immunotherapy with anti-GD2 monoclonal antibodies. The next generation of trials are designed to improve the initial response rates in patients with high-risk neuroblastomas via the addition of immunotherapies, targeted therapies (such as ALK inhibitors) and radiopharmaceuticals to standard induction regimens. Other trials are focused on testing precision medicine strategies for patients with relapsed and/or refractory disease, enhancing the antitumour immune response and improving the effectiveness of maintenance regimens, in order to prolong disease remission. In this Review, we describe advances in delineating the pathogenesis of neuroblastoma and in identifying the drivers of high-risk disease. We then discuss how this knowledge has informed improvements in risk stratification, risk-adapted therapy and the development of novel therapies.
- 25 May 2022
- Published by Springer Nature in Nature Reviews Clinical Oncology
- Vol. 19 (8) , 515-533
Top Cited PapersAdvancing therapy for neuroblastoma
Neuroblastomas are tumours of sympathetic origin, with a heterogeneous clinical course ranging from localized or spontaneously regressing to widely metastatic disease. Neuroblastomas recapitulate many of the features of sympathoadrenal development, which have been directly targeted to improve the survival outcomes in patients with high-risk disease. Over the past few decades, improvements in the 5-year survival of patients with metastatic neuroblastomas, from 50%, have resulted from clinical trials incorporating high-dose chemotherapy with autologous stem cell transplantation, differentiating agents and immunotherapy with anti-GD2 monoclonal antibodies. The next generation of trials are designed to improve the initial response rates in patients with high-risk neuroblastomas via the addition of immunotherapies, targeted therapies (such as ALK inhibitors) and radiopharmaceuticals to standard induction regimens. Other trials are focused on testing precision medicine strategies for patients with relapsed and/or refractory disease, enhancing the antitumour immune response and improving the effectiveness of maintenance regimens, in order to prolong disease remission. In this Review, we describe advances in delineating the pathogenesis of neuroblastoma and in identifying the drivers of high-risk disease. We then discuss how this knowledge has informed improvements in risk stratification, risk-adapted therapy and the development of novel therapies.